<DOC>
	<DOC>NCT02047318</DOC>
	<brief_summary>The purpose of this extension study is to determine the long-term safety and tolerability of an investigational treatment (LUM001) in children with ALGS who have completed participation in the LUM001-302 study.</brief_summary>
	<brief_title>An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Alagille Syndrome</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<criteria>Male or female, 12 months to 18 years of age. Competent to provide informed consent and assent (per IRB/EC), as appropriate. Completed participation in study LUM001302. Females of childbearing potential must have a negative urine pregnancy test. Sexually active females must be prepared to use an effective method of contraception during the trial. Subjects above the age of assent and caregivers and children must be able to read and understand English. Caregivers (and age appropriate subjects) must have access to phone for scheduled calls from study site. Caregivers (and age appropriate subjects) must be willing and able to complete a daily electronic diary (ItchRO) during the first consecutive 12 weeks of the study and then for 4 consecutive weeks following the Week 24 and Week 44 visits. Caregivers (and age appropriate subjects) must digitally accept the licensing agreement in the ItchRO electronic diary software at the outset of the study. Experienced an adverse event or serious adverse event (SAE) related to the study drug during the LUM001302 protocol that led to the discontinuation of the subject from the core study. Any conditions or abnormalities (including laboratory abnormalities) which, in the opinion of the Investigator or the Sponsor Medical Monitor, may compromise the safety of the subject, or interfere with the subject participating in or completing the study. History or presence of gallstones or kidney stones. History of nonadherence during the subject's participation in the LUM001302 protocol. Nonadherence is defined by dosing compliance of less than 80% in the LUM001302 protocol. Unlikely to comply with the study protocol, or unsuitable for any other reason, as judged by the investigator.</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>